

Curriculum Vitae

Personal information **Roberto Frontini**

Work experience

1. EMA (European Medicines Agency)
 - Start date: 052022
 - End date:
 - Position: Member of PRAC
 - Activities: Representing healthcare professionals at Pharmacovigilance Risk assessment Committee
 - Country: Netherland
2. EMA (European Medicines Agency)
 - Start date: 062019
 - End date: 022022
 - Position: Alternate member of PRAC
 - Activities: Representing healthcare professionals at Pharmacovigilance Risk assessment Committee
 - Country: Netherland
3. Employer: Zentrum für Arzneimitteltherapie Sicherheit
 - Start date: 072015
 - End date: 122017
 - Position: Director for patient care
 - Activities: responsible for the clinical part of projects related to drug_therapy safety
 - Country: Germany
4. Employer: EAHP (European Association of Hospital Pharmacists)
 - Start date: 062015
 - End date: 062017
 - Position: Immediate Past President
 - Activities: Member of the board
 - Country: Belgium
5. Employer: Universitätsklinikum Leipzig AöR
 - Start date: 082012
 - End date: 122017
 - Position: Qualified Person (QP)
 - Activities: Responsible for release of Investigational Medicine Products (IMP) and Patient individual preparations
 - Country: Germany
6. Employer: EAHP (European Association of Hospital Pharmacists)
 - Start date: 062009
 - End date: 062015
 - Position: President
 - Activities: Head of board, responsible for the policy of the association, representing the association internationally
 - Country: Belgium
7. Employer: EAHP (European Association of Hospital Pharmacists)
 - Start date: 062005
 - End date: 062009
 - Position: Director of Finances
 - Activities: Member of the board, responsible for the finances of the association
 - Country: Belgium
8. Employer: Universität Leipzig
 - Start date: 102004
 - End date: 022018
 - Position: Lecturer
 - Activities: Lecture on Pharmacoepidemiology and Pharmacoeconomics
 - Country: Germany
9. Employer: Universitätsklinikum Leipzig AöR
 - Start date: 072001
 - End date: 122017
 - Position: Director of Pharmacy
 - Activities: Responsible for Pharmacy Services. CEO of Drug &Therapeutic Committee
 - Country: Germany
10. Employer: St.Franziskus Hospital Cologne

- Start date: 071996
 - End date: 062001
 - Position: Head of Pharmacy
 - Activities: Responsible for Pharmacy Services. CEO of Drug &Therapeutic Committee
 - Country: Germany
11. Employer: Chamber of Pharmacy, Hannover
- Start date: 031994
 - End date: 052005
 - Position: Trainer
 - Activities: Trainer for pharmaceutical technology Seminars of Hospital Pharmacy specialisation
 - Country: Germany
12. Employer: Universitätsklinik Lübeck
- Start date: 071992
 - End date: 121995
 - Position: Pharmacist
 - Activities: Responsible for oncology preparations, pharmaceutical technology
 - Country: Germany
13. Employer: University of Hamburg, Institute of Pharmaceutical Technology
- Start date: 101988
 - End date: 061992
 - Position: Assistant
 - Activities: Seminars on pharmaceutical Technology
 - Country: Germany
14. Employer: Hansa Apotheke Lübeck
- Start date: 041988
 - End date: 091988
 - Position: Pharmacist
 - Activities:
 - Country: Germany
15. Employer: Gymnasium Bad Segeberg
- Start date: 091981
 - End date: 061983
 - Position: Teacher
 - Activities: Teaching Music
 - Country: Germany
16. Employer: Theatre of Lübeck
- Start date: 081976

Education and training

1. Subject: University Hospital of Leipzig
 - Start date: 082010
 - End date: 082013
 - Qualification: Qualified Person
 - Organisation: Qualified Person for release of Investigational Medicine Products (IMP)
 - Country: Germany
2. Subject: Apothekerkammer Schleswig Holstein
 - Start date: 071992
 - End date: 061995
 - Qualification: Specialisation in Hospital Pharmacy
 - Organisation: Additional training in hospital and clinical pharmacy
 - Country: Germany
3. Subject: University of Hamburg
 - Start date: 061988
 - End date: 111992
 - Qualification: PhD (Dr.rer.nat.)
 - Organisation: Postgraduate study on pharmaceutical Technology and stability of preparations
 - Country: Germany
4. Subject: University of Hamburg
 - Start date: 101983
 - End date: 051988
 - Qualification: Pharmacist
 - Organisation: Pharmacy education
 - Country: Germany
5. Subject: Musikhochschule Frankfurt/Main
 - Start date: 101971
 - End date: 061976
 - Qualification: Conductor
 - Organisation: Conducting, Piano, Composition
 - Country: Germany
6. Subject: Goethe University of Frankfurt/Main
 - Start date: 101969
 - End date: 061971
 - Qualification: no qualification
 - Organisation: Study on Musicology and Philosophy
 - Country: Germany
7. Subject: School
 - Start date: 101956
 - End date: 071969
 - Qualification: Esame di maturità
 - Organisation: Basic education
 - Country: Italy

Additional information

Publications

• Frontini R. Wie „nützlich“ sind Orphan Drugs? Auch Arzneimittel für seltene Krankheiten müssen ihre klinische Effektivität zeigen. Deutsche Apotheker Zeitung 2022;162(12):30_32. • Frontini R. Wachsame Augen für sichere Arzneimittel. Pharmakovigilanz ist auch eine europäische Aufgabe. Uni_DAZ 2022;1:36_37. • Kuruc_Poje D, Kifer D, Huys I, Miranda J, Jenzer H, Miljković N, Hoppe_Tichy T, Bochniarz M, Frontini R, Schwartz DG, Vujić_Aleksić V, Nežić L, Rinaki E, Tzimis L, Green K, Jovanić J, Carić B, Mandić D, Vilić K, Bochenek T, Bačić Vrcić V, Marušić S. Patients perspectives on drug shortages in six European hospital settings – a cross sectional study. BMC Health Services Research 2021; 21: 689. <https://doi.org/10.1186/s12913-021-06721-9>. • Frontini R. Das Dilemma der SARS_CoV_2_Impfstoffbeurteilung. Deutsche Apotheker Zeitung 2021;161(15):38_39. • Frontini R. Europäische Behörde unter Zeitdruck. Uni_DAZ 2021;1:28_30. • Neining MP, Buchholz P, Frontini R, Kiess W, Siekmeyer W, Bertsche A, Siekmeyer M, Bertsche T. Incompatible intravenous drug combinations and respective physician and nurse knowledge: a study in routine paediatric intensive care. Eur J Hosp Pharm. 2019;26(4):214_217. • Lingor P, Weber M, Camu W, Friede T, Hilgers R, Leha A, Neuwirth C, Günther R, Benatar M, Kuzma_Kozakiewicz M, Bidner H, Blankenstein C, Frontini R, Ludolph A, Koch JC. ROCK_ALS: Protocol for a Randomized, Placebo_Controlled, Double_Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis. Front Neurol. 2019;10:293. • Jansen_Winkeln B, Thieme R, Haase L, Niebisch S, Pommer C, Lyros O, Zimmer J, Lordick F, Remane Y, Frontini R, Gockel I. Perioperative safety of intraperitoneal aerosol chemotherapy : Analysis of our first 111 pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedures. Chirurg. 2019;90(2):137_145. • West LM, Vetter_Kerkhoff C, Miljkovic N, Frontini R. Is there a need for a hospital pharmacy common training framework? Review of the literature on the impact of educational interventions on health outcome. Eur J Hosp Pharm. 2018;25(1):6_9. • Pfeifer C, Noll S, Gerecke H, Fassauer G, Jira T, Remane Y, Vogel J, Frontini R, Reinhardt R. A stability study of amphotericin B, colistin and tobramycin in a hydrophilic suspension commonly used for selective decontamination of the digestive tract by HPLC and in vitro potency measurements. Eur J Hosp Pharm. 2017;24(4):235_241. • Bertsche T, Schiek S, Neining MP, Frontini R. Die Arzneimitteltherapie der Patienten sicherer machen Interdisziplinäre Konzepte am Leipziger Zentrum für Arzneimittelsicherheit. Med Monatsschr Pharm. 2017;40(4):171_3. • Zimmer J, Hartl S, Standfuß K, Möhn T, Bertsche A, Frontini R, Neining MP, Bertsche T. Handling of hazardous drugs _ Effect of an innovative teaching session for nursing students. Nurse Educ Today. 2017;49:72_78. • Frontini R. Falsified Medicines Directive: Are We Heading in the Right Direction? Medicine Access @ Point of Care. 2017;1, e55_e57. • Schiek S, Moritz K, Seichter SJ, Ghanem M, von Salis_Soglio G, Frontini R, Bertsche T. Standardising analgesic administration for nurses: a prospective intervention study. Int J Clin Pharm. 2016;38(6):1497_1504. • Coughlin DJ, Chen TF, Frontini R, Al Hail M, Hattin J, Kurosawa N, Savio E. Advancing responsible use of medicines globally: The revised Basel Statements.American Journal of Health_System Pharmacy 2016;73 (14):1027_1028. • Kaune A, Schumacher PM, Hoppe SC, Syrbe S, Bernhard MK, Frontini R, Merckenschlager A, Kiess W, Neining MP, Bertsche A, Bertsche T. Administration of anticonvulsive rescue medication in children_discrepancies between parents' self_reports and limited practical performance. Eur J Pediatr. 2016;175(9):1139_1146. • Frontini R. In the shade of old pines. Am J Health Syst Pharm. 2016;73(13):991_5. • Schiek S, Ghanem M, Frontini R, Hertel G, von Salis_Soglio G, Bertsche T. Pain assessment in routine care : A prospective observational study in an orthopedic unit. Schmerz. 2016;30(3):257_65. • Zimmer J, Remane Y, Frontini R, Bertsche T. Herstellung applikationsfertiger oraler fester Zytostatika_Zubereitungen, Onkologische Pharmazie 2016; 18(2): 24_28. • Zimmer J, Niemann D, Seltmann K, Fischer L, Christiansen H, Frontini R, Kiess W, Neining MP, Bertsche A, Bertsche T. Managing of oral medicines in paediatric oncology: can a handbook and a pharmaceutical counselling intervention for patients and their parents prevent knowledge deficits? A pilot study. Eur J Hosp Pharm. 2016;23(2):100_105. • Frontini R. Warum der p_Wert uns nur in die Irre führt_ Oder warum Zahlen nicht immer ein guter Beweis sind. Krankenhauspharmazie 2015;36:381-3. • Neining MP, Ullmann M, Dahse AJ, Syrbe S, Bernhard MK, Frontini R, Kiess W, Merckenschlager A, Thome U, Bertsche T, Bertsche A. Use of Levetiracetam in Neonates in Clinical Practice: A Retrospective Study at a German University Hospital. Neuropediatrics. 2015;46(5):329_34. • Schiek S, Hildebrand C, Ranft D, Dürrbeck A, Ghanem M, von Salis_Soglio G, Frontini R, Bertsche T. A cohort study investigating medication management by pharmacists to prevent drug_related problems in pain therapy, Eur J Hosp Pharm 2015; 22:156_160. • Schubert S, Neining MP, Smers S, Winter A, Frontini R, Bertsche A, Bertsche T. Electronic drug prescription _ auto pilot for drug therapy? Med Monatsschr Pharm. 2015;38(6):224_30. • Pfeifer C, Fassauer G, Gerecke H, Jira T, Remane Y, Frontini R, Byrne J, Reinhardt R. Purity determination of amphotericin B, colistin sulfate and tobramycin sulfate in a hydrophilic suspension by HPLC. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 ;990:7_14. • Bertsche T, Lindner S, Damm M, Frontini R, Exner C, Himmerich H. An interdisciplinary concept to optimize patient safety_a pilot study. Psychiatr Prax. 2015;42(4):216_20. • Schnoor J, Rogalski C, Frontini R, Engelmann N, Heyde CE. Case report of a medication error by look_alike packaging: a classic surrogate marker of an unsafe system. Patient Saf Surg. 2015;9:12. • Neining MP, Kaune A, Bertsche A, Rink J, Musiol J, Frontini R, Prenzel F, Kiess W, Bertsche T. How to improve prescription of inhaled salbutamol by providing standardised feedback on administration: a controlled intervention pilot study with follow_up. BMC Health Serv Res. 2015;15:40. • Bertsche A, Neining MP, Dahse AJ, Syrbe S, Bernhard MK, Frontini R, Kiess W, Bertsche T, Merckenschlager A. Initial anticonvulsant monotherapy in routine care of children and adolescents: levetiracetam fails more frequently than valproate and oxcarbazepine due to a lack of effectiveness. Eur J Pediatr. 2014;173(1):87_92. • Frontini R. The statements: a reflection on the results. Eur J Hosp Pharm 2014;21(5): 256_258. • Preece D, Holme K, Frontini R, Tromp D, Price R. Admission into primary care: are we doing enough? Eur J Hosp Pharm. 2014;21: 79_83. • Frontini R, Kubica U, Burjanko S, Bödeker H, Bertsche T. Leitlinienkonformität in der Antibiotikatherapie, Krankenhauspharmazie 2014;35 (3): 67-71. • Bertsche A, Dahse AJ, Neining MP, Bernhard MK, Syrbe S, Frontini R, Kiess W, Merckenschlager A, Bertsche T. Ambulatory care of children treated with anticonvulsants _ pitfalls after discharge from hospital. Klin Padiatr. 2013;225(5):277_82. • Frontini R, Miharija_Gala T, Sykora J. EAHP Survey 2010 on hospital pharmacy in Europe: part 6. Education and research. Eur J Hosp Pharm. 2013;20: 253_256. • Frontini R, Miharija_Gala T, Sykora J. EAHP Survey 2010 on hospital pharmacy in Europe: parts 4 and 5. Clinical services and patient safety. Eur J Hosp Pharm. 2013;20:69_73. • Schneider R, Ranft D, Heintz K, Uhlmann D, Hauss J, Frontini R, Leinung S. Pharmaceutical care in a visceral surgical ward. Zentralbl Chir. 2012 Apr;137(2):173_9. • Frontini R, Miharija_Gala T, Sykora J. EAHP Survey 2010 on hospital pharmacy in Europe: part 3. Production and quality assurance. Eur J Hosp Pharm. 2012;19:510_513. • Frontini R, Miharija_Gala T, Sykora J. EAHP Survey 2010 on hospital pharmacy in Europe: part 2. Procurement and distribution. Eur J Hosp Pharm. 2012;19:460_463. • Frontini R, Miharija_Gala T, Sykora J. EAHP Survey 2010 on hospital pharmacy in Europe: part 1. General frame and staffing, European Journal of Hospital Pharmacy, 2012;19:385_387. • Frontini R. More harm than good? Problems surrounding the regulation of prescription medication in Europe. Public Service Review Europe Union, 2010;20:139_140. • Remane Y, Schwulera U, Frontini R. Planung eines GMP_Bereichs in einer Krankenhausapotheke. Krankenhauspharmazie 2008;29:128-33. • Schäfer K, Frontini R, Nieber K. Wie hoch ist die Datenqualität der Arzneimittelanamnese? Ergebnisbericht einer Patientenbefragung zur Haus_ und Klinikmedikation. Krankenhauspharmazie 2007; 28: 43_46. • Engel A, Frontini R. Modulare Versorgung mit Arzneimitteln. Krankenhauspharmazie, 2006;27(1): 17-23. • Frontini R. Wirksamkeit, Effektivität und Effizienz. Wie relevant sind die Ergebnisse von Studien für die klinische Praxis? Krankenhauspharmazie, 2004;25(1):1_7. • Frontini R, Vogel J. Das AXON_Bildererkennungssystem. Krankenhauspharmazie, 2003;24(2): 50_53. • Frontini R. Thromboseprophylaxe und Pharmakoökonomie. PantaRei 2001;1:14_15. • Frontini R, Seitz HJ. Qualitätsmanagement, Arzneimittelumsatz und Pharmakoökonomie. Erfahrungen mit dem Programm RaTh©. Krankenhauspharmazie 2001; 22(2): 69_72. • Frontini R. Evidenz Basierte Medizin als Grundlage einer pharmakoökonomischen Evaluation. Krankenhauspharmazie, 2000; 21(5): 213_217. • Frontini R, Mielck JB. Interactions between bendroflumethiazide and water soluble polymers. II. Factors promoting drug_polymer association. Eur. J. Pharm. Biopharm.1997;43:309_314. • Frontini R, Mielck JB. Interactions between bendroflumethiazide and water soluble polymers. I. Solubility of bendroflumethiazide in water from solid dispersions and formation of associates under climatic stress. Eur. J. Pharm. Biopharm.1997;43:185_191. • Frontini R, Mielck JB. Interactions between bendroflumethiazide and water soluble polymers. III. Chemical degradation. Eur. J. Pharm. Biopharm.1997;43:85_88. • Frontini R, Mielck JB. Formation of formaldehyde in polyethyleneglycol and poloxamer under stress conditions. Int. J. Pharm. 1995;114:121_123. • Frontini R, Mielck JB. Determination and quantitation of bendroflumethiazide and its degradation products using HPLC. J.Liq.Chromat. 1992;15(14): 2519_2528.

Projects

Single unit and barcoding Patient safety (Projects of University of Leipzig) EAHP Survey on Hospital Pharmacy Summit on Hospital Pharmacy COST Action 15105 (Medicine shortages) Common Training Framework for Hospital Pharmacy EAHP SIG Automation in hospitals

Memberships

Member of ADKA (German Association of Hospital Pharmacists) Member of EAHP (European Association of Hospital Pharmacists)

Other Relevant Information

I am a patient representative